Wyeth Effexor XR
Executive Summary
Journal advertisements for venlafaxine using the tag lines "beyond better to well" and "bring patients to true wellness" draw objections from FDA in an Oct. 11 letter to the company. The antidepressant's claims imply "that it will be unlikely that condition will return," the letter states. FDA instructs Wyeth to cease similar advertisements for the extended release capsules. Wyeth is preparing a response to the letter
You may also be interested in...
Wyeth Effexor Claim Of Superiority To SSRIs Challenged; Radio Ad Also Cited
FDA is challenging Wyeth Effexor/Effexor XR promotions that suggest the antidepressant is more effective than SSRIs
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011